ABSTRACT

Nanocapsules can be compared to vesicular systems in which the drug is trapped in a cavity that encloses an internal fluid surrounded by a polymeric membrane. Nanocapsules show promise as active vectors because of their ability to release drugs; their small cell size allows for higher intracellular acquisition than other particle systems. The nanocapsule can be directed to specific cells and areas within the body after intravenous and subcutaneous injections. The formation of a nanocapsule is a mixture between a polymeric nanocapsule and a liposome due to its oily substance surrounded by a strong pressure-acting membrane. The advantage of the encapsulation method is to protect these objects to be protected in the wrong place, to be controlled and precisely identified. Deflazacort is a glucocorticoid with a high glucocorticoid receptor affinity but low systemic function due to excessive initial metabolism in the liver. Deflazacort has a short half-life from 1.1-1.9 hours. So it is ready for further release. Lipidic nanocapsule was developed that will provide greater stability and reduce drug toxicity. Keywords: Nanocapsules, Deflazacort, Liposomes, Glucocorticoids
Publication date: 25/01/2022

https://ijbpas.com/pdf/2022/January/MS_IJBPAS_2022_JAN_SPCL_2_2056.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2022/11.1.2056